Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024 Investing 1 Min Read

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your name
Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Popular
- S&P 500 Breakdown Alert! Downside Targets Explained
  January 13, 2025 Stock 4 Mins Read
- Tech 5: AI Takes Center Stage at CES, NVIDIA Unveils Cosmos Platform
  January 13, 2025 Investing 7 Mins Read
- Appointment of Chief Executive Officer
  January 13, 2025 Investing 1 Min Read
Categories
- Business (69)
- Economy (72)
- Investing (136)
- Stock (77)